key: cord-0923775-uw9wh71b
authors: Acharya, Arpan; Pathania, Anup S.; Pandey, Kabita; Thurman, Michellie; Vann, Kendra R.; Kutateladze, Tatiana G.; Challagundala, Kishore B.; Durden, Donald L.; Byrareddy, Siddappa N.
title: PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron
date: 2022-04-07
journal: Clin Transl Med
DOI: 10.1002/ctm2.806
sha: 71b7bce140053ca809114cbcbffc246564e82c2b
doc_id: 923775
cord_uid: uw9wh71b

nan

are expected to produce more robust, durable treatment options. Therefore, we tested the anti-viral potential of SF2523 against the wild-type SARS-CoV-2 and VOCs. In UNCN1T (a bronchial epithelial cell line), Vero STAT1 KO and Calu-3 cells, the CC 50 value of SF2523 is above 100 μM ( Figure 1A Figure 2D ), respectively. Since BRD4 promotes lung tissue fibrosis through an increase in the expression of pro-fibrotic genes, and the majority of severely ill COVID-19 patients suffer from pulmonary fibrosis, 6 the inclusion of BRD4 inhibitor SF2523 in COVID-19 therapy will benefit patients to recover from lung fibrosis. This is further supported by a recent study showing that BET protein inhibition blocks cardiac irregularities and SARS-CoV-2 infection 7 and may be useful to controlling the long COVID-19 effects recently seen in many recovered patients.

Combining multiple drugs with different modes of action has synergistic effects and has been used as antivirals. Therefore, we evaluated a series of fixed-dose combinations of SF2523 and RDV or MU-UNMC-2. 1 The combined doses of SF2523/RDV and SF2523/MU-UNMC-2 have CC50 values above 100 μM ( Figure S2B F I G U R E 1 Cytotoxicity and wild-type SARS-CoV-2 replication inhibition dose-response curves of SF2523 in UNCN1T and Vero STAT1 KO cells. (A, B) Cytotoxicity of SF2523 in UNCN1T and Vero STAT1 KO cells was measured by MTT assay. The cells were treated with increasing concentration of SF2523 (0.001-100 μM) and incubated at 37 • C in a humidified 5% CO 2 incubator. Seventy-two hours post-treatment, 20 μl of MTT substrate (5 mg/ml) was added to each well and incubated for 4 additional hours at 37 • C in the dark. Then, the culture media was carefully removed, and blue formazan crystals were dissolved in 200 μl of DMSO, and the purple colour was read at 595 nm with a reference filter of 620 nm. In both the cells, SF2523 has a CC 50 value above 100 μM. (C, D) UNCN1T and Vero STAT1 knockout cells (20,000 cells/well) were seeded in 96-well plates 24 h before infection. Different concentrations of SF2523 and remdesivir (100, 10, 5, 1, 0.1, 0.01 and 0.001 μM) were added to the cells 2 h before infection. The cells were infected with 0.1 MOI of SARS-CoV-2 isolate USA-WI1/2020 (BEI Cat # NR52384). Culture supernatant was collected 24 h post-infection. The SARS-CoV-2 viral load was quantified in the culture supernatant using RT-qPCR with primer probes targeting E gene of SARS-CoV-2 using PrimeDirect Probe RT-qPCR Mix (TaKaRa Bio USA, Inc) and Applied Biosystems QuantStudio3 real-time PCR system (Applied Biosystems, Waltham, MA, USA) as per the manufacturer's instructions. The SARS-CoV-2 genome equivalent copies were calculated using quantitative PCR (qPCR) control RNA from heat-inactivated SARS-CoV-2, isolate USA-WA1/2020 (BEI, Catalog# NR-52347). The percentage inhibition of SARS-CoV-2 replication in SF2523 and remdesivir-treated wells was calculated with respect to viral concentration in positive control wells treated with DMSO (considered 0% inhibition) and negative control wells (uninfected cells). SF2523 (in blue) and remdesivir (in green) IC 50 values were calculated using four-parameter variable slope sigmoidal dose-response models using Graph Pad Prism 8.0 software; [CC 50 : drug concentration that is required to reduce cell viability by 50%; IC 50 : drug concentration that is required to reduce the viral replication by 50%] an IC 50 value of 0.62 μM ( Figure 3A ) that is lower than individual IC 50 of both the compounds. The dose-response percent inhibition matrix of single and combination treatment of SF2523/RDV and SF2523/MU-UNMC-2 is described in Figure 3B and E. The 3D interaction landscape of SF2523/RDV and SF2523/MU-UNMC-2 was computed based on Loewe additive model using SynergyFinder v.2 ( Figure 3C and F). The synergistic/antagonistic effects of drug combinations are reconfirmed using Chou and Talalay combination index (CI) theorem 8 [CI < 1: synergism; = 1: additive effect; > 1: antagonism]. Using Com-puSyn, we computed CI values of SF2523/RDV as CI < 1 and CI of SF2523/MU-UNMC-2 as 0.129, confirming their synergistic effect. For SF2523/RDV, we obtained a dose reduction index (DRI) of 25.33 and 3.75 for SF2523 and RDV, and for SF2523/MU-UNMC-2, we obtained the DRI of 23.03 and 11.56 for SF2523 and MU-UNMC-2, respectively. This synergistic effect of SF2523 with RDV or MU-UNMC-2 is expected in a favourable shift in the plasma Cmax/EC 90 ratio. Next, using NMR titration experiments by labelling 15 N-labelled BRD4 domains, we showed that RDV is not able to bind to either BRD4-BD1, BRD4-BD2 or the ET domain of BRD4, as no significant chemical shift perturbations were observed in 1 H, 15 N heteronuclear single quantum coherence spectra of these domains (Figure 4 ). This confirms that RDV does not alter the [CC 50 : drug concentration that is required to reduce cell viability by 50%; IC 50 : drug concentration that is required to reduce the viral replication by 50%] potency of SF2523 and does not interfere with the binding of SF2523 to BRD4.

It is documented that SARS-CoV-2 infection in mammalian cells inhibits autophagy through various mechanisms, including the activation of autophagy inhibitory proteins (AKT1 and SKP2) and inhibition of proteins involved in autophagy initiation (AMPK, TSC2, Unc-51 Like Autophagy Activating Kinase 1 and Beclin 1), autophagosome formation (VPS34) and in membrane tethering and fusion of autophagosomes to endolysosomes (ATG14) 9 and SARS-CoV-2, and its transmembrane protein ORF3a inhibits autophagy. Activating autophagy using small molecules that target PI3Kinase/Akt pathway or stabilize Beclin inhibits SARS-CoV-2 replication. 9 Our studies suggest that SF2523 may be modulating the autophagy mechanisms ( Figure S3 ) to limit SARS-CoV-2 infection similar to previously reported HIVinfected macrophages restrict infection through autophagy induction, 10 although this warrants further in-depth investigation.

In conclusion, we demonstrated that SF2523 could inhibit the replication of SARS-CoV-2 and its VOCs. Further, we found a synergistic effect of SF2523 with RDV or MU-UNMC-2 in a wide dose range. Therefore, we conclude that SF2523 (a PI3K-α/mTOR/BRD4 inhibitor) alone or combined with other anti-virials represents a future therapeutic approach to prevent the severe disease associated with SARS-CoV-2 and its VOCs. 

Remdesivir does not interfere with the interaction between SF2523 and BRD4. BRD4 15 N-labelled BD1 (amino acids 43-180), BD2 (amino acids 342-460) and ET domain (amino acids 600-700) were expressed in Escherichia coli. Superimposed 1 H, 15 N heteronuclear single quantum coherence (HSQC) spectra of uniformly 15 N-labelled BD1 (left), BD2 (middle) and ET (right) domains of BRD4 with the indicated ligands added in a stepwise manner. Two-dimensional 1 H, 15 N HSQC spectra were acquired on a 600 MHz Varian spectrometer fitted with a cryogenic probe at 298 K. Spectra were processed with NMRPipe. The spectra are colour-coded according to the protein: ligand ratios. Small resonance changes are due to weak binding of DMSO, which was confirmed by titrating DMSO alone to separate samples of these domains (data not shown)

We acknowledge the UNMC BSL-3 core facility for allowing us to perform all in vitro experiments involving SARS-CoV-2. The University of Nebraska Medical Center BSL-3 Core Facility is administrated through the Office of the Vice-Chancellor for Research and supported by the Nebraska Research Initiative (NRI).

Discovery and evaluation of entry inhibitors for SARS-CoV-2 and its emerging variants

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2

COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers hosttargeting antivirals

Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication